Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.

@article{Piechotta2020ConvalescentPO,
  title={Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.},
  author={Vanessa Piechotta and Khai Li Chai and Sarah J. Valk and Carolyn J Doree and Ina Monsef and Erica M. Wood and Abigail Lamikanra and Catherine Kimber and Zoe K. McQuilten and Cynthia So-Osman and Lise J. Estcourt and Nicole Skoetz},
  journal={The Cochrane database of systematic reviews},
  year={2020},
  volume={7},
  pages={
          CD013600
        }
}
BACKGROUND Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are currently being investigated in trials as potential therapy for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding the benefits and risks is required.  OBJECTIVES: To continually assess, as more evidence becomes available, whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and… Expand
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
TLDR
The overall certainty of evidence was low to very low, due to study limitations and results including both potential benefits and harms, according to Cochrane Childhood Cancer for non-controlled NRSIs. Expand
Convalescent plasma may be a possible treatment for COVID-19: A systematic review
  • Ying Wang, P. Huo, +7 authors Kun Zhu
  • Medicine
  • International Immunopharmacology
  • 2021
TLDR
Although the results of limited RCTs showed that Convalescent plasma(CP) immunotherapy cannot significantly reduce mortality, some non-RCTs and case report(series) have found that CP may help patients improve clinical symptoms, clear the virus, and reduce deaths, especially for patients with COVID-19 within ten days of illness. Expand
Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review
TLDR
The published literature data seem to indicate that convalescent plasma administered to pregnant women with severe COVID-19 provides benefits for both the mother and the fetus, although the quality of the available studies is very limited. Expand
The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review
TLDR
There is insufficient clinical information on the safety and efficacy of convalescent plasma therapy in children with COVID-19, but the positive outcomes of the few case reports published to date suggest that convalescence plasma therapy may be of potential benefit. Expand
Convalescent Plasma Therapy for Coronavirus Disease 2019
  • J. Choi
  • Medicine
  • Infection & chemotherapy
  • 2020
TLDR
Convalescent plasma therapy should be considered as a candidate therapy for COVID-19 given the limited effectiveness of antiviral drugs and lack of a vaccine, and a system to secure safe collection and use of convalescence plasma should be developed as a response to the pandemic. Expand
Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective
TLDR
The findings indicate that CPT shows potential in reducing the severity and duration of COVID-19 symptoms, however, early intervention, recruitment of donors, and plasma potency introduce major challenges for its scaled-up implementation. Expand
Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study
TLDR
Convalescent plasma (CP) therapy may be a potential therapeutic option in severe or critically ill patients with COVID-19 and showed a higher increase in Ct values at 24 h and 72 h after CP therapy compared to controls with similar initial Ct values. Expand
Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.
TLDR
It is shown that the vast majority of patients already had potent neutralizing SARS-CoV-2 antibodies at hospital admission and with comparable titers to carefully selected plasma donors, which resulted in the decision to terminate the trial prematurely. Expand
Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
TLDR
Despite the variability in the certainty of the evidence, the results of this umbrella review highlight a mortality reduction in CP over standard therapy when administered early and at high titer, without increased adverse reactions. Expand
Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis
TLDR
Compared with later initiation of CBP therapy, earlier initiation of this therapy may decrease the rate of mortality, and based on the outcomes of RCTs, CBPs may not decrease all-cause mortality. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 178 REFERENCES
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
TLDR
Assessing whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19 found all-cause mortality at hospital discharge, improvement of clinical symptoms, grade 3 and 4 adverse events, and serious adverse events were reported. Expand
Convalescent plasma to treat coronavirus disease 2019 (COVID‐19): considerations for clinical trial design
Case series studying convalescent plasma use in the treatment of COVID‐19 have been promising, but additional, high‐quality studies are needed to determine the efficacy of the treatment when appliedExpand
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
TLDR
Convalescent plasma may reduce mortality and appears safe, and should be studied within the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East respiratory syndrome coronavirus CoV infection. Expand
Convalescent plasma treatment of severe COVID-19: A matched control study
TLDR
Convalescent plasma transfusion is a potentially efficacious treatment option for patients hospitalized with severe to life-threatening COVID-19; however, these data suggest that non-intubated patients may benefit more than those requiring mechanical ventilation. Expand
Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas
TLDR
The data indicate that administration of convalescent plasma is a safe treatment option for those with severe COVID-19 disease and Randomized, controlled trials are needed to determine its efficacy. Expand
Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma
TLDR
The successful treatment of this 100-year-old patient using convalescent plasma suggests that it should be added in the management of the elderly, and significant improvement was observed on laboratory indicators and clinical symptoms of the patient. Expand
Convalescent Plasma Therapy for Coronavirus in Critically ill Patients
TLDR
Convalescent plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies, and may offer the only short-term strategy to confer immediate immunity to susceptible individuals. Expand
[Convalescent Plasma for Treatment of Severe COVID-19: Rationale and Designing of a Randomized, Open-Label Clinical Trial of Convalescent Plasma Compared to Best Supportive Care (CAPSID Trial)]
TLDR
A prospective randomized clinical trial is designed to study the safety and efficacy of convalescent plasma for treatment of severe COVID-19 and its mechanism of action (CAPSID trial). Expand
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
TLDR
CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases and the optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials. Expand
Convalescent Plasma for COVID-19. A randomized clinical trial
TLDR
The Convalescent-plasma-for-COVID study was a randomized trial comparing convalescent plasma with standard of care therapy in patients hospitalized for COVID-19 in the Netherlands and found no difference in mortality, hospital stay, or day-15 disease severity was observed between plasma treated patients and patients on standard of Care. Expand
...
1
2
3
4
5
...